Literature DB >> 23661430

Putative tumor suppressor gene SEL1L was downregulated by aberrantly upregulated hsa-mir-155 in human pancreatic ductal adenocarcinoma.

Qian Liu1, Jinyun Chen, Jin Wang, Christopher Amos, Ann M Killary, Subrata Sen, Chongjuan Wei, Marsha L Frazier.   

Abstract

Sel-1-like (SEL1L) is a putative tumor suppressor gene that is significantly downregulated in human pancreatic ductal adenocarcinoma (PDA). The mechanism of the downregulation is unclear. Here, we investigated whether aberrantly upregulated microRNAs (miRNAs) repressed the expression of SEL1L. From reported miRNA microarray studies on PDA and predicted miRNA targets, we identified seven aberrantly upregulated miRNAs that potentially target SEL1L. We assessed the expression levels of SEL1L mRNA and the seven miRNAs in human PDA tumors and normal adjacent tissues using real-time quantitative polymerase chain reaction. Then statistical methods were applied to evaluate the association between SEL1L mRNA and the miRNAs. Furthermore, the interaction was explored by functional analysis, including luciferase assay and transient miRNA overexpression. SEL1L mRNA expression levels were found to correlate inversely with the expression of hsa-mir-143, hsa-mir-155, and hsa-mir-223 (P < 0.0001, P < 0.0001, and P = 0.002, respectively). As the number of these overexpressed miRNAs increased, SEL1L mRNA expression progressively decreased (Ptrend  = 0.001). Functional analysis revealed that hsa-mir-155 acted as a suppressor of SEL1L in PDA cell lines. Our study combined statistical analysis with biological approaches to determine the relationships between several miRNAs and the SEL1L gene. The finding that the expression of the putative tumor suppressor SEL1L is repressed by upregulation of hsa-mir-155 helps to elucidate the mechanism for SEL1L downregulation in some human PDA cases. Our results suggest a role for specific miRNAs in the pathogenesis of PDA and indicate that miRNAs have potential as therapeutic targets for PDA.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  Ingenuity Pathways Analysis; gene expression regulation; microRNA; reverse phase protein assay

Mesh:

Substances:

Year:  2013        PMID: 23661430      PMCID: PMC3887131          DOI: 10.1002/mc.22023

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  37 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  SEL1L expression decreases breast tumor cell aggressiveness in vivo and in vitro.

Authors:  Rosaria Orlandi; Monica Cattaneo; Flavia Troglio; Patrizia Casalini; Chiara Ronchini; Sylvie Ménard; Ida Biunno
Journal:  Cancer Res       Date:  2002-01-15       Impact factor: 12.701

3.  Establishment of a new human pancreatic adenocarcinoma cell line, MDAPanc-3.

Authors:  M L Frazier; S Pathak; Z W Wang; K Cleary; S E Singletary; M Olive; B Mackay; P A Steck; B Levin
Journal:  Pancreas       Date:  1990       Impact factor: 3.327

4.  Immortalization with telomerase of the Nestin-positive cells of the human pancreas.

Authors:  K M Lee; C Nguyen; A B Ulrich; P M Pour; M M Ouellette
Journal:  Biochem Biophys Res Commun       Date:  2003-02-21       Impact factor: 3.575

5.  Classification of pancreatic cancer (nonendocrine).

Authors:  A L Cubilla; P J Fitzgerald
Journal:  Mayo Clin Proc       Date:  1979-07       Impact factor: 7.616

6.  SEL1L expression in pancreatic adenocarcinoma parallels SMAD4 expression and delays tumor growth in vitro and in vivo.

Authors:  Monica Cattaneo; Simonetta Orlandini; Stefania Beghelli; Patrick S Moore; Claudio Sorio; Antonio Bonora; Claudio Bassi; Giorgio Talamini; Giuseppe Zamboni; Rosaria Orlandi; Sylvie Ménard; Luigi Rossi Bernardi; Ida Biunno; Aldo Scarpa
Journal:  Oncogene       Date:  2003-09-25       Impact factor: 9.867

7.  mRNA turnover rate limits siRNA and microRNA efficacy.

Authors:  Erik Larsson; Chris Sander; Debora Marks
Journal:  Mol Syst Biol       Date:  2010-11-16       Impact factor: 11.429

8.  Conserved regulation of p53 network dosage by microRNA-125b occurs through evolving miRNA-target gene pairs.

Authors:  Minh T N Le; Ng Shyh-Chang; Swea Ling Khaw; Lingzi Chin; Cathleen Teh; Junliang Tay; Elizabeth O'Day; Vladimir Korzh; Henry Yang; Ashish Lal; Judy Lieberman; Harvey F Lodish; Bing Lim
Journal:  PLoS Genet       Date:  2011-09-15       Impact factor: 5.917

9.  Complete mutation scanning of the human SEL 1L gene: a candidate gene for type 1 diabetes.

Authors:  Z M Larsen; A D Angelo; M Cattaneo; J Nerup; I Biunno; M Zollo; F Pociot
Journal:  Acta Diabetol       Date:  2001-12       Impact factor: 4.280

Review 10.  Comparing protein abundance and mRNA expression levels on a genomic scale.

Authors:  Dov Greenbaum; Christopher Colangelo; Kenneth Williams; Mark Gerstein
Journal:  Genome Biol       Date:  2003-08-29       Impact factor: 13.583

View more
  22 in total

1.  Down-modulation of SEL1L, an unfolded protein response and endoplasmic reticulum-associated degradation protein, sensitizes glioma stem cells to the cytotoxic effect of valproic acid.

Authors:  Monica Cattaneo; Simona Baronchelli; Davide Schiffer; Marta Mellai; Valentina Caldera; Gloria Jotti Saccani; Leda Dalpra; Antonio Daga; Rosaria Orlandi; Pasquale DeBlasio; Ida Biunno
Journal:  J Biol Chem       Date:  2013-12-05       Impact factor: 5.157

2.  Tumor-suppressive function of long noncoding RNA MALAT1 in glioma cells by suppressing miR-155 expression and activating FBXW7 function.

Authors:  Shuanzhu Cao; Yanzhou Wang; Jinquan Li; Mingliang Lv; Haitao Niu; Yong Tian
Journal:  Am J Cancer Res       Date:  2016-11-01       Impact factor: 6.166

3.  Methylation-associated silencing of MicroRNA-335 contributes tumor cell invasion and migration by interacting with RASA1 in gastric cancer.

Authors:  Zhengrong Li; Daojiang Li; Guoyang Zhang; Jianbo Xiong; Zhigang Jie; Heping Cheng; Yi Cao; Mengmeng Jiang; Liangqing Lin; Zhibiao Le; Shengxing Tan; Wenyu Zou; Binbin Gong; Shengrong Lin; Ke Yang
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

4.  MicroRNA-155 promotes apoptosis in SKOV3, A2780, and primary cultured ovarian cancer cells.

Authors:  Wei Chen; Liuxuan Huang; Chenjun Hao; Wenshu Zeng; Xu Luo; Xiaodi Li; Longshu Zhou; Songshan Jiang; Zheng Chen; Yuanli He
Journal:  Tumour Biol       Date:  2016-01-15

Review 5.  MicroRNA in pancreatic cancer.

Authors:  Keiichi Yonemori; Hiroshi Kurahara; Kosei Maemura; Shoji Natsugoe
Journal:  J Hum Genet       Date:  2016-06-02       Impact factor: 3.172

6.  Overexpression of microRNA-155 predicts poor prognosis in glioma patients.

Authors:  Jun Sun; Huachao Shi; Niansheng Lai; Keman Liao; Shuai Zhang; Xiaojie Lu
Journal:  Med Oncol       Date:  2014-03-13       Impact factor: 3.064

7.  Next generation sequencing of pancreatic cyst fluid microRNAs from low grade-benign and high grade-invasive lesions.

Authors:  Jin Wang; Pamela L Paris; Jinyun Chen; Vy Ngo; Hui Yao; Marsha L Frazier; Ann M Killary; Chang-Gong Liu; Han Liang; Christian Mathy; Sandhya Bondada; Kimberly Kirkwood; Subrata Sen
Journal:  Cancer Lett       Date:  2014-10-07       Impact factor: 8.679

Review 8.  Epigenetic regulation of microRNAs in gastric cancer.

Authors:  Jiaojiao Ma; Liu Hong; Zheng Chen; Yongzhan Nie; Daiming Fan
Journal:  Dig Dis Sci       Date:  2013-11-19       Impact factor: 3.199

9.  SEL1L SNP rs12435998, a predictor of glioblastoma survival and response to radio-chemotherapy.

Authors:  Marta Mellai; Monica Cattaneo; Alessandra Maria Storaci; Laura Annovazzi; Paola Cassoni; Antonio Melcarne; Pasquale De Blasio; Davide Schiffer; Ida Biunno
Journal:  Oncotarget       Date:  2015-05-20

10.  MicroRNAs Deregulated in Intraductal Papillary Mucinous Neoplasm Converge on Actin Cytoskeleton-Related Pathways That Are Maintained in Pancreatic Ductal Adenocarcinoma.

Authors:  Elena Fernandez-Castañer; Maria Vila-Casadesus; Elena Vila-Navarro; Carolina Parra; Juan Jose Lozano; Antoni Castells; Meritxell Gironella
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.